Last reviewed · How we verify
Ergocalciferol 50000 UNT
Ergocalciferol (vitamin D2) is converted in the body to its active form, which regulates calcium and phosphate absorption and homeostasis.
Ergocalciferol (vitamin D2) is converted in the body to its active form, which regulates calcium and phosphate absorption and homeostasis. Used for Vitamin D deficiency, Hypoparathyroidism, Rickets.
At a glance
| Generic name | Ergocalciferol 50000 UNT |
|---|---|
| Sponsor | University of Alabama at Birmingham |
| Drug class | Vitamin D supplement |
| Target | Vitamin D receptor (VDR) |
| Modality | Small molecule |
| Therapeutic area | Endocrinology / Nutritional deficiency |
| Phase | FDA-approved |
Mechanism of action
Ergocalciferol is a fat-soluble vitamin that is metabolized in the liver to 25-hydroxyvitamin D2 and then in the kidneys to the active form 1,25-dihydroxyvitamin D2. This active metabolite acts as a hormone, binding to vitamin D receptors in the intestines, bones, and kidneys to promote calcium absorption, maintain serum calcium and phosphate levels, and support bone mineralization and immune function.
Approved indications
- Vitamin D deficiency
- Hypoparathyroidism
- Rickets
- Osteomalacia
Common side effects
- Hypercalcemia
- Hypercalciuria
- Nausea
- Vomiting
- Constipation
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ergocalciferol 50000 UNT CI brief — competitive landscape report
- Ergocalciferol 50000 UNT updates RSS · CI watch RSS
- University of Alabama at Birmingham portfolio CI